Literature DB >> 18056004

A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy.

Marie von Lilienfeld-Toal1, Corinna Hahn-Ast, Hartmut Kirchner, Dimitri Flieger, Gottfried Dölken, Axel Glasmacher.   

Abstract

We randomized 66 elderly patients with AML unfit for conventional chemotherapy to receive GCSF from d6 or from d12 after induction-chemotherapy with cytarabine/idarubicin. There was no difference in duration of neutropenia (17 days vs. 19 days, p=0.67) or rate of complications. Delayed treatment can reduce the administration of G-CSF without adverse consequences.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18056004     DOI： 10.3324/haematol.11516

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  3 in total

Review 1.  Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.

Authors:  Ronit Gurion; Yulia Belnik-Plitman; Anat Gafter-Gvili; Mical Paul; Liat Vidal; Isaac Ben-Bassat; Ofer Shpilberg; Pia Raanani
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

2.  Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.

Authors:  Karin Mayer; Corinna Hahn-Ast; Sara Mückter; Andrea Schmitz; Simon Krause; Linda Felder; Isabelle Bekeredjian-Ding; Ernst Molitor; Peter Brossart; Marie von Lilienfeld-Toal
Journal:  Support Care Cancer       Date:  2015-01-24       Impact factor: 3.603

3.  XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

Authors:  A del Giglio; A Eniu; D Ganea-Motan; E Topuzov; H Lubenau
Journal:  BMC Cancer       Date:  2008-11-12       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.